Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Citatuzumab, an antibody targeting EPCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvizumab, an antibody targeting HIV-1 gp120.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fresolimumab, an antibody targeting TGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fezakinumab, an antibody targeting IL22.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vesencumab, an antibody targeting NRP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Samalizumab, an antibody targeting MOX2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enavatuzumab, an antibody targeting TNFRSF12A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atinumab, an antibody targeting RTN4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solitomab, an antibody targeting EPCAM × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Narnatumab, an antibody targeting MST1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Flanvotumab, an antibody targeting TYRP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Perakizumab, an antibody targeting IL-17A.